The search for novel compounds of relevance to the treatment of diseases caused by trypanosomatid protozoan parasites continues. Screening of a large library of known bioactive compounds has led to several drug-like starting points for further optimisation. In this study, novel analogues of the monoamine uptake inhibitor indatraline were prepared and assessed both as inhibitors of trypanothione reductase (TryR) and against the parasite Trypanosoma brucei. Although it proved difficult to significantly increase the potency of the original compound as an inhibitor of TryR, some insight into the preferred substituent on the amine group and in the two aromatic rings of the parent indatraline was deduced. In addition, detailed mode of action studies indicated that two of the inhibitors exhibit a mixed mode of inhibition.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3047706 | PMC |
| http://dx.doi.org/10.1002/cmdc.201000442 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development of novel dual-target drugs against visceral leishmaniasis and combinational study with miltefosine.
Free Radic Biol Med
November 2024
School of Biochemical Engineering, Indian Institute of Technology (BHU), Varanasi 221005, Uttar Pradesh, India. Electronic address:
Article Synopsis
- Two dual-target inhibitors (ZINC000008876351 and ZINC000253403245) were discovered using advanced computational methods to inhibit critical enzymes FeSODA and TryR in Leishmania donovani, showing strong enzyme inhibition in low μM concentrations.
- Flow cytometry results indicated that these compounds significantly increased reactive oxygen species (ROS) levels in treated cells, suggesting they effectively disrupt the parasite's antioxidant defense.
- The inhibitors demonstrated dose-dependent anti-leishmanial activity against both stages of the parasite and showed a synergistic effect when combined with miltefosine, which is especially relevant due to rising resistance against miltefosine in some Leishmania strains.
Molecular Docking-Based Virtual Screening of FDA-Approved Drugs Using Trypanothione Reductase Identified New Trypanocidal Agents.
Molecules
August 2024
Departamento de Parasitología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Ciudad de México 07738, Mexico.
American trypanosomiasis or Chagas disease, caused by (), affects approximately 6-7 million people worldwide. However, its pharmacological treatment causes several uncomfortable side effects, causing patients' treatment abandonment. Therefore, there is a need for new and better treatments.
View Article and Find Full Text PDFIdentification of Novel Antileishmanial Chemotypes By High-Throughput Virtual and In Vitro Screening.
Acta Parasitol
September 2024
Department of Biochemistry, Abdul Wali Khan University Mardan, Mardan, Pakistan.
Background: Leishmaniasis is a deadly protozoan parasitic disease and a significant health problem in underdeveloped and developing countries. The global spread of the parasite, coupled with the emergence of drug resistance and severe side effects associated with existing treatments, has necessitated the identification of new and potential drugs.
Objective: This study aimed to identify promising compounds for the treatment of leishmaniasis by targeting two essential enzymes of Leishmania donovani: trypanothione reductase (Try-R) and trypanothione synthetase (Try-S).
Targeting Trypanothione Metabolism in Trypanosomatids.
Molecules
May 2024
Departamento de Ciencias Biomédicas, Facultad de Veterinaria, Universidad de León, Campus de Vegazana s/n, 24071 León, Spain.
Infectious diseases caused by trypanosomatids, including African trypanosomiasis (sleeping sickness), Chagas disease, and different forms of leishmaniasis, are Neglected Tropical Diseases affecting millions of people worldwide, mainly in vulnerable territories of tropical and subtropical areas. In general, current treatments against these diseases are old-fashioned, showing adverse effects and loss of efficacy due to misuse or overuse, thus leading to the emergence of resistance. For these reasons, searching for new antitrypanosomatid drugs has become an urgent necessity, and different metabolic pathways have been studied as potential drug targets against these parasites.
View Article and Find Full Text PDFInsights of potential trypanocidal effect of the synthetic derivative (2E)-1-(4-aminophenyl)-3-(2,4-dichlorophenyl)prop-2-en-1-one: in vitro assay, MEV analysis, quantum study, molecular docking, molecular dynamics, MPO analysis, and predictive ADMET.
Naunyn Schmiedebergs Arch Pharmacol
October 2024
Center for Exact Sciences and Technology, State University of Vale do Acaraú, Sobral, CE, Brazil.
This study aims to evaluate the antitrypanosomiasis activity of a synthetic dichloro-substituted aminochalcone via in vitro assays against infected cell cultures, as well as a theoretical characterization of pharmacokinetics and pharmacodynamics against the protein targets of the evolutionary cycle of T. cruzi. The in vitro evaluation of parasite proliferation inhibition was performed via cytotoxicity analysis on mammalian host cells, effect on epimastigote and trypomastigote forms, and cell death analysis, while computer simulations characterized the electronic structure of (2E)-1-(4-aminophenyl)-3-(2,4-dichlorophenyl)prop-2-en-1-one (DCl), the mechanism of action against the proteins of the evolutionary cycle of T.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!